{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-052731","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.318667+00:00","generated_at":"2026-06-08T04:37:54.160075+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Galectin Therapeutics Q3 net loss $14M; cash $20.4M; Chairman exercises warrants for $10M","bullets":["Net loss $14.0M ($0.24/sh) vs $8.6M ($0.14/sh) YoY; includes $3.6M non-cash deemed dividend from warrant modification.","Cash and equivalents $20.4M at Sept 30; additional $30M available under chairman's credit line.","Chairman Uihlein exercised 2.2M warrants at $4.49/sh for $10M gross proceeds; Dr. Benjamin Carson nominated to board.","R&D expenses $7.7M (up from $6.6M) on hiring and belapectin activities; G&A $1.4M (down from $1.5M).","Interim analysis for NAVIGATE belapectin trial on track for Q4 2023; company believes funded through Dec 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-052731","json":"https://secwatch.observer/filing/0001140361-23-052731.json","markdown":"https://secwatch.observer/filing/0001140361-23-052731.md","text":"https://secwatch.observer/filing/0001140361-23-052731.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123052731/0001140361-23-052731-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123052731/ef20014482_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:37:54.160075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7d24bc750f1d55dba8307f1a2de49b8718b8e7b","claim":"GALECTIN THERAPEUTICS INC reported the three months ended September 30, 2023 results: net income net loss applicable to common stockholders of $14.0 million, or ($0.24) per share, EPS ($0.24) per share.","evidence_excerpt":"For the three months ended September 30, 2023, the Company reported a net loss applicable to common stockholders of $14.0 million, or ($0.24) per share, compared to a net loss applicable to common stockholders of $8.6 million, or ($0.14) per share for the three months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123052731/0001140361-23-052731-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Net income","value":"net loss applicable to common stockholders of $14.0 million, or ($0.24) per share"},{"label":"EPS","value":"($0.24) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}